4,871 Shares in Incyte Co. (NASDAQ:INCY) Purchased by Sivia Capital Partners LLC

Sivia Capital Partners LLC purchased a new position in Incyte Co. (NASDAQ:INCY) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 4,871 shares of the biopharmaceutical company’s stock, valued at approximately $295,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Retirement Systems of Alabama increased its stake in Incyte by 0.4% in the 4th quarter. Retirement Systems of Alabama now owns 34,620 shares of the biopharmaceutical company’s stock worth $2,391,000 after purchasing an additional 139 shares in the last quarter. Nissay Asset Management Corp Japan ADV increased its stake in Incyte by 0.7% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 20,371 shares of the biopharmaceutical company’s stock worth $1,410,000 after purchasing an additional 150 shares in the last quarter. Bank of Nova Scotia increased its stake in Incyte by 0.8% in the 4th quarter. Bank of Nova Scotia now owns 21,694 shares of the biopharmaceutical company’s stock worth $1,498,000 after purchasing an additional 171 shares in the last quarter. Newman Dignan & Sheerar Inc. grew its stake in Incyte by 4.0% during the 4th quarter. Newman Dignan & Sheerar Inc. now owns 5,222 shares of the biopharmaceutical company’s stock valued at $361,000 after acquiring an additional 200 shares in the last quarter. Finally, Catalyst Financial Partners LLC grew its stake in Incyte by 2.7% during the 4th quarter. Catalyst Financial Partners LLC now owns 7,493 shares of the biopharmaceutical company’s stock valued at $518,000 after acquiring an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Insider Buying and Selling

In other news, EVP Barry P. Flannelly sold 19,807 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the completion of the transaction, the executive vice president now directly owns 33,567 shares in the company, valued at $2,272,150.23. The trade was a 37.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 17.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on INCY shares. Morgan Stanley lowered their target price on Incyte from $69.00 to $65.00 and set an “equal weight” rating on the stock in a research note on Monday, March 24th. JMP Securities reaffirmed a “market perform” rating on shares of Incyte in a research note on Tuesday, February 11th. Wells Fargo & Company lifted their target price on Incyte from $58.00 to $59.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 30th. Royal Bank of Canada lifted their target price on Incyte from $64.00 to $67.00 and gave the company a “sector perform” rating in a research note on Wednesday, April 30th. Finally, Stifel Nicolaus lifted their target price on Incyte from $75.00 to $77.00 and gave the company a “hold” rating in a research note on Monday, February 10th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Incyte presently has an average rating of “Hold” and an average target price of $72.53.

Incyte Stock Up 2.3%

INCY opened at $68.77 on Monday. The business has a 50 day moving average price of $61.44 and a 200 day moving average price of $67.15. Incyte Co. has a twelve month low of $53.56 and a twelve month high of $83.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.94 and a current ratio of 1.97. The firm has a market cap of $13.31 billion, a P/E ratio of 254.71, a price-to-earnings-growth ratio of 0.41 and a beta of 0.67.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $1.16 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.15. Incyte had a return on equity of 0.05% and a net margin of 0.77%. The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $996.17 million. During the same period in the previous year, the company earned $0.64 EPS. The company’s revenue for the quarter was up 19.5% on a year-over-year basis. Research analysts forecast that Incyte Co. will post 4.86 EPS for the current year.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.